Why the study?
Although the Ross operation shows excellent long-term outcomes, pulmonary homograft dysfunction represents a key disadvantage requiring intervention on two valves.
What are the long-term outcomes and predictors of pulmonary homograft dysfunction after the Ross procedure in adults with aortic valve disease?
What are the long-term outcomes and predictors of pulmonary homograft dysfunction after the Ross procedure in adults with aortic valve disease?
The Ross procedure using fresh pulmonary homografts in adults demonstrates excellent long-term survival and low reoperation rates, though pulmonary homograft dysfunction occurs in about a third of patients at 10 years, particularly in younger patients.
Supports low reoperation after Ross in adults; extends observational durability data while leaving open mitigation strategies for younger patients.
The Ross procedure was first proposed by Donald Ross in 1967. Numerous studies show excellent long-term outcomes of the Ross operation. One of its disadvantages is the intervention on two valves due to pulmonary homograft dysfunction. Aim. To study long-term outcomes of pulmonary homograft use after Ross operation (cumulative incidence of pulmonary homograft dysfunction, freedom from reoperation on pulmonary homograft, long-term survival, predictors of pulmonary homograft dysfunction) using data from one Russian center. Material and methods . A retrospective study included patients aged 18 years and older with aortic valve disease who underwent Ross procedure from April 2009 to December 2020 by a single surgeon. The age of the patients was 35 (26-44) years (men, 159 (75%)). Infective endocarditis as a cause of aortic valve pathology was diagnosed in 55 (26%) patients. Bicuspid aortic valve was diagnosed in 131 (62%) patients. The median follow-up period was 79 (26,5102,7) months. Results. Combined interventions were performed in 40 cases (18,9%). The modified Ross procedure was used in 54 (25,5%) cases (intra-aortic — 29, using Dacron tube graft — 25). Inhospital mortality was 0,5%. The 5- and 10-year allcause survival rates were 98,5% and 95,4%, while the 10-year cumulative pulmonary valve reoperation rate and pulmonary homograft dysfunction was 4,6% and 35,2%, respectively. The only factor affecting pulmonary homograft dysfunction was patient age ≤30 years (odds ratio =0,2 with 95% confidence interval: 0,06-0,7; p=0,02). Conclusion. Fresh pulmonary homografts have a low incidence of dysfunction and reintervention after Ross procedure. Young age is the only independent risk factor for pulmonary homograft dysfunction.
No takes yet. Share an insight, caveat, or question.
Enginoev et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: